Saisindhu Narala, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Narala’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A172013 · Current
Licensed to practise in California · since 2021 · expires 2027-03-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$52,041
Medicare paid this office $52,041 for 307 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 97 | $14,778 | $87 |
| Short return visit (20+ min) | 153 | $11,668 | $58 |
| Destruction of skin growth, 1-14 growths | 65 | $5,520 | $64 |
| Destruction of precancer skin growth, 1 growth | 81 | $4,218 | $43 |
| New patient visit (45+ min) | 39 | $4,033 | $103 |
See all 15 services
| Return visit (30+ min) | 97 | $14,778 | $87 |
| Short return visit (20+ min) | 153 | $11,668 | $58 |
| Destruction of skin growth, 1-14 growths | 65 | $5,520 | $64 |
| Destruction of precancer skin growth, 1 growth | 81 | $4,218 | $43 |
| New patient visit (45+ min) | 39 | $4,033 | $103 |
| New patient visit (30+ min) | 50 | $3,611 | $72 |
| Biopsy of related skin growth, first growth | 64 | $1,666 | $23 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $1,433 | $90 |
| Biopsy of related skin growth, each additional growth | 23 | $678 | $20 |
| Injection into skin growth, 1-7 growths | 12 | $625 | $23 |
| New patient visit (15+ min) | 11 | $492 | $45 |
| Punch biopsy, first skin growth | 13 | $462 | $33 |
| Destruction of precancer skin growth, 2-14 growths | 63 | $355 | $2 |
| Short return visit | 11 | $268 | $24 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 16 | $254 | $15 |
Procedures Medicare counted
| Removal of skin lesions | 528 | More than 87% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 176 | More than 83% of doctors who do this |
Who their Medicare patients are
307 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 12% · Women 60% · Also on Medicaid 24% · Health risk score 1.21. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 64% · Diabetes 26% · Chronic kidney disease 22% · Coronary heart disease 17% · Cancer 15% · Atrial fibrillation 15% · Heart failure 14% · Depression 14% · COPD 10% · Stroke 9% · Dementia 5%.
The office billed $225,587, Medicare allowed $70,626 and paid $52,041; for 1,067 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 307 | 1,067 | 73 | 1.21 | $225,587 | $52,041 |
| 2023 | 249 | 823 | 72 | 1.39 | $163,526 | $36,273 |
| 2022 | 72 | 161 | 68 | 1.54 | $32,276 | $6,997 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Short return visit (20+ min) | 122 | $9,421 | $57 |
| Return visit (30+ min) | 43 | $6,146 | $83 |
| New patient visit (30+ min) | 69 | $4,614 | $67 |
| New patient visit (45+ min) | 32 | $3,723 | $116 |
| Destruction of precancer skin growth, 1 growth | 58 | $3,407 | $45 |
| Destruction of skin growth, 1-14 growths | 39 | $3,213 | $63 |
| Biopsy of related skin growth, first growth | 40 | $1,164 | $25 |
| Injection into skin growth, 1-7 growths | 15 | $773 | $24 |
| Biopsy of related skin growth, each additional growth | 13 | $645 | $21 |
| Punch biopsy, first skin growth | 11 | $532 | $41 |
| Short return visit | 18 | $530 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $360 | $2 |
2022: 4 services
| Short return visit (20+ min) | 29 | $1,808 | $60 |
| New patient visit (30+ min) | 18 | $1,259 | $70 |
| Destruction of precancer skin growth, 1 growth | 15 | $697 | $46 |
| Short return visit | 13 | $421 | $32 |
Medicaid work
$2,607 in 2024
Medicaid paid $2,607 for 41 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 41 | $2,607 |
| 2024 | 41 | 1 | 13 | $2,607 |
Drugs they prescribed that Part D paid
$501,272
Pharmacies billed $501,272 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 671) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
573 generic and 98 brand-name prescriptions · $501,272 in drug cost · 20 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 40 | $137,582 | $3,440 |
| Dupixent | 12 | $40,363 | $3,364 |
| Fluocinonide | 57 | $1,801 | $32 |
| Ketoconazole | 102 | $1,725 | $17 |
| Tacrolimus | 17 | $1,457 | $86 |
See all 19 drugs
| Dupixent | 40 | $137,582 | $3,440 |
| Dupixent | 12 | $40,363 | $3,364 |
| Fluocinonide | 57 | $1,801 | $32 |
| Ketoconazole | 102 | $1,725 | $17 |
| Tacrolimus | 17 | $1,457 | $86 |
| Fluorouracil | 18 | $1,389 | $77 |
| Isotretinoin | 16 | $1,188 | $74 |
| Halobetasol Propionate | 12 | $1,046 | $87 |
| Betamethasone Diprop Augmented | 12 | $878 | $73 |
| Clobetasol Propionate | 27 | $875 | $32 |
| Dapsone | 12 | $636 | $53 |
| Triamcinolone Acetonide | 59 | $575 | $10 |
| Doxycycline Hyclate | 18 | $544 | $30 |
| Ciclopirox | 13 | $479 | $37 |
| Clindamycin Phosphate | 14 | $289 | $21 |
| Ciclopirox | 14 | $161 | $11 |
| Mupirocin | 13 | $102 | $8 |
| Hydrocortisone | 21 | $73 | $3 |
| Finasteride | 12 | $65 | $5 |
Year by year
| 2024 | 671 | 183 | 0% (0) | 15% | $501,272 |
| 2023 | 573 | 163 | 0% (0) | 12% | $243,500 |
| 2022 | 92 | 49 | 0% (0) | None | $61,473 |
| 2021 | 34 | 21 | 0% (0) | 0% | $1,568 |
| 2020 | 189 | 83 | 0% (0) | 13% | $130,234 |
| 2019 | 185 | 89 | 0% (0) | 8% | $22,627 |
| 2018 | 160 | 54 | 0% (0) | None | $10,749 |
| 2017 | 78 | 26 | 0% (0) | None | $4,546 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Dupixent | 27 | $105,299 | $3,900 |
| Otezla | 16 | $78,392 | $4,900 |
| Clobetasol Propionate | 31 | $1,945 | $63 |
| Ketoconazole | 64 | $1,594 | $25 |
| Fluocinonide | 30 | $1,419 | $47 |
| Betamethasone Diprop Augmented | 17 | $993 | $58 |
| Betamethasone Dipropionate | 15 | $962 | $64 |
| Doxycycline Hyclate | 19 | $856 | $45 |
| Triamcinolone Acetonide | 75 | $773 | $10 |
| Fluorouracil | 13 | $761 | $59 |
| Ciclopirox | 26 | $466 | $18 |
| Nystatin | 17 | $401 | $24 |
| Hydrocortisone | 29 | $193 | $7 |
| Fluconazole | 16 | $160 | $10 |
| Mupirocin | 15 | $159 | $11 |
2022: 1 drug
| Triamcinolone Acetonide | 15 | $241 | $16 |
2020: 5 drugs
| Tacrolimus | 21 | $17,935 | $854 |
| Clobetasol Propionate | 13 | $686 | $53 |
| Fluocinonide | 11 | $642 | $58 |
| Triamcinolone Acetonide | 23 | $466 | $20 |
| Ketoconazole | 12 | $284 | $24 |
2019: 7 drugs
| Tacrolimus | 11 | $4,729 | $430 |
| Fluorouracil | 11 | $1,532 | $139 |
| Metronidazole | 12 | $1,168 | $97 |
| Fluocinonide | 12 | $1,047 | $87 |
| Doxycycline Monohydrate | 17 | $1,023 | $60 |
| Ketoconazole | 13 | $474 | $36 |
| Triamcinolone Acetonide | 22 | $421 | $19 |
2018: 2 drugs
| Atorvastatin | 11 | $345 | $31 |
| Pantoprazole | 12 | $317 | $26 |
Money from drug and device companies
$100 in 2022
A payment is not proof that care is biased.
See all 2 published payments
| Pfizer | Meals · 2022-03-27 | Cibinqo | $24 |
| Abbvie | Meals · 2022-03-26 | Rinvoq | $77 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1205368008
- Licence
- CA A172013California A172013: Current · expires 2027-03-31
- Trained
- University of California, San Diego School of Medicine, 2017
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2017-03-30
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.